PMID- 29931526 OWN - NLM STAT- MEDLINE DCOM- 20190503 LR - 20240405 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 36 IP - 12 DP - 2018 Dec TI - An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. PG - 1981-1995 LID - 10.1007/s00345-018-2380-x [doi] AB - OBJECTIVES: With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette-Guerin (BCG) therapy. METHODS AND MATERIALS: A medline/pubmed(c) literature search was performed. The performance of commercially available and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and response to BCG therapy. RESULTS: The performance requirements for biomarkers are variable according to the clinical scenario. The clinical role of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased drug development strategy. CONCLUSIONS: Current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be needed to establish their clinical relevance and value. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Droller, Michael J AU - Droller MJ AD - Department of Urology, The Mount Sinai Medical Center, New York, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Hopital Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris Sorbonne Universite, Paris, France. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Weill Cornell Medical College, New York, USA. shahrokh.shariat@meduniwien.ac.at. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Review DEP - 20180621 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM CIN - World J Urol. 2019 Sep;37(9):1985-1986. PMID: 30600353 MH - Aftercare/*methods MH - BCG Vaccine/administration & dosage MH - Biomarkers, Tumor/*urine MH - Humans MH - Neoplasm Recurrence, Local/diagnosis/*urine MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/drug therapy/*urine PMC - PMC6280823 OTO - NOTNLM OT - Follow-up OT - Non-muscle invasive bladder cancer OT - Recurrence OT - Surveillance OT - Test OT - Urinary biomarker COIS- CONFLICT OF INTEREST: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is an advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Wolff. He is the speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff. ETHICAL STANDARDS: This study was conducted according to the Declaration of Helsinki. EDAT- 2018/06/23 06:00 MHDA- 2019/05/06 06:00 PMCR- 2018/06/21 CRDT- 2018/06/23 06:00 PHST- 2018/04/11 00:00 [received] PHST- 2018/06/15 00:00 [accepted] PHST- 2018/06/23 06:00 [pubmed] PHST- 2019/05/06 06:00 [medline] PHST- 2018/06/23 06:00 [entrez] PHST- 2018/06/21 00:00 [pmc-release] AID - 10.1007/s00345-018-2380-x [pii] AID - 2380 [pii] AID - 10.1007/s00345-018-2380-x [doi] PST - ppublish SO - World J Urol. 2018 Dec;36(12):1981-1995. doi: 10.1007/s00345-018-2380-x. Epub 2018 Jun 21.